| 1. |
- Chen, LC, et al.
(författare)
-
Excitation transfer in polymer photodiodes for enhanced quantum efficiency
- 2000
-
Ingår i: Advanced Materials. - 0935-9648 .- 1521-4095. ; 12:15, s. 1110-
-
Tidskriftsartikel (refereegranskat)abstract
- The realization of polymer solar cells is the driving force behind this research. In an idea inspired by photosynthesis, the authors have constructed efficient bilayer photodiodes by a well-chosen combination of conjugated polymers (see Figure) in the donor layer. Forster energy transfer within the donor layer allows the absorbed light to be channeled to the C-60 acceptor layer, improving the total photoconversion of the blend device.
|
|
| 2. |
- Chen, LC, et al.
(författare)
-
Self organised polymer photodiodes for extended spectral coverage
- 2000
-
Ingår i: Thin Solid Films. - 0040-6090 .- 1879-2731. ; 363:1-2, s. 286-289
-
Tidskriftsartikel (refereegranskat)abstract
- We report the use of self organised blends of conjugated polymers for improving the spectral coverage of the solar spectrum, and in this way to enhance solar energy conversion efficiency in photodiodes and solar cells. (C) 2000 Elsevier Science S.A. All rights reserved.
|
|
| 3. |
|
|
| 4. |
|
|
| 5. |
- Roman, LS, et al.
(författare)
-
Photovoltaic devices based on photo induced charge transfer in polythiophene : CN-PPV blends
- 2003
-
Ingår i: Brazilian journal of physics. - 0103-9733 .- 1678-4448. ; 33:2, s. 376-381
-
Tidskriftsartikel (refereegranskat)abstract
- We have investigated the photovoltaic properties of polymer devices based on a blend of two polymers, (poly(3-(2'-methoxy-5'-octylphenyl) thiophene) (POMeOPT) and poly(2,5,2',5'-tetrahexyloxy-7,8'-dicyanodi-p-phenylenevinylene) (CN-PPV), where photo induced charge transfer takes place at the interfaces formed by the interpenetrating network of the donor and the acceptor. The polymer blend films resulting from the spin coating were phase separated and the photo response of the devices depended on the morphology of the segregation. We have studied different blend ratios by photoluminescence quenching, scanning force microscopy and photovoltaic measurements. External quantum efficiencies of 4.5% at 500nm were achieved for the less segregated polymer blend.
|
|
| 6. |
- Roman, LS, et al.
(författare)
-
Trapping light in polymer photodiodes with soft embossed gratings
- 2000
-
Ingår i: Advanced Materials. - 0935-9648 .- 1521-4095. ; 12:3, s. 189-
-
Tidskriftsartikel (refereegranskat)abstract
- Increasing the conversion efficiency is very important in photovoltaic devices, as is cheap and simple technology. Here is demonstrated a soft embossing technique for printing a submicrometer grating with an elastomeric mold into an optically active polymer layer in a photovoltaic device (see Figure). The light trapping due to the grating pattern enhances the photoconversion efficiency by more than 25 % at normal light incidence (see also inside front cover).
|
|
| 7. |
- Ruilope, LM, et al.
(författare)
-
Design and Baseline Characteristics of the Finerenone in Reducing Cardiovascular Mortality and Morbidity in Diabetic Kidney Disease Trial
- 2019
-
Ingår i: American journal of nephrology. - : S. Karger AG. - 1421-9670 .- 0250-8095. ; 50:5, s. 345-356
-
Tidskriftsartikel (refereegranskat)abstract
- <b><i>Background:</i></b> Among people with diabetes, those with kidney disease have exceptionally high rates of cardiovascular (CV) morbidity and mortality and progression of their underlying kidney disease. Finerenone is a novel, nonsteroidal, selective mineralocorticoid receptor antagonist that has shown to reduce albuminuria in type 2 diabetes (T2D) patients with chronic kidney disease (CKD) while revealing only a low risk of hyperkalemia. However, the effect of finerenone on CV and renal outcomes has not yet been investigated in long-term trials. <b><i>Patients and</i></b> <b><i>Methods:</i></b> The Finerenone in Reducing CV Mortality and Morbidity in Diabetic Kidney Disease (FIGARO-DKD) trial aims to assess the efficacy and safety of finerenone compared to placebo at reducing clinically important CV and renal outcomes in T2D patients with CKD. FIGARO-DKD is a randomized, double-blind, placebo-controlled, parallel-group, event-driven trial running in 47 countries with an expected duration of approximately 6 years. FIGARO-DKD randomized 7,437 patients with an estimated glomerular filtration rate ≥25 mL/min/1.73 m<sup>2</sup> and albuminuria (urinary albumin-to-creatinine ratio ≥30 to ≤5,000 mg/g). The study has at least 90% power to detect a 20% reduction in the risk of the primary outcome (overall two-sided significance level α = 0.05), the composite of time to first occurrence of CV death, nonfatal myocardial infarction, nonfatal stroke, or hospitalization for heart failure. <b><i>Conclusions:</i></b> FIGARO-DKD will determine whether an optimally treated cohort of T2D patients with CKD at high risk of CV and renal events will experience cardiorenal benefits with the addition of finerenone to their treatment regimen. Trial Registration: EudraCT number: 2015-000950-39; ClinicalTrials.gov identifier: NCT02545049.
|
|
| 8. |
|
|
| 9. |
|
|
| 10. |
|
|
